Adicet Bio, Inc. (ACET)

Market Cap	825.32M
Revenue (ttm)	30.46M
Net Income (ttm)	-55.73M
Shares Out	41.64M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	639,770
Open	19.42
Previous Close	19.26
Day's Range	18.86 - 20.9
52-Week Range	9.88 - 21.87
Beta	1.71
Analysts	Buy
Price Target	28.65 (+41.9%)
Earnings Date	Nov 9, 2022

About ACET

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company a...

• Industry: Health Care Providers & Services
• Founded: 1947
• CEO: Chen Schor
• Employees: 86
• Stock Exchange: NASDAQ
• Ticker Symbol: ACET

Financial Performance

In 2021, Adicet Bio's revenue was $9.73 million, a decrease of -45.65% compared to the previous year's $17.90 million. Losses were -$62.00 million, 69.0% more than in 2020.

Analyst Forecast

According to 17 analysts, the average rating for ACET stock is "Buy." The 12-month stock price forecast is 28.65, which is an increase of 41.90% from the latest price.

Price Target

$28.65

(41.90% upside)

Analyst Consensus: Buy